The fifth batch of countries have arrows on the string, can Chinese medicine take care of itself?

What are the difficulties in incorporating Chinese medicine into centralized procurement?

Quantity purchasing and consistency evaluation are a combination of punches.
Without consistency evaluation, quantity purchasing cannot be implemented
.
However, the biggest technical difficulty of adding Chinese medicine to purchase in quantity is how to realize the "consistency evaluation" of Chinese medicine? The biggest difficulty in achieving "consistency evaluation" of traditional Chinese medicine lies in "standards
.
"

Most Chinese medicine products can only be defined by treatment location or treatment field, and it is difficult to measure by consistency evaluation standards.
Some proprietary Chinese medicines have unclear indications and wide clinical applications.
It is difficult to achieve a reasonable delineation of indications.
Larger
.

Secondly, most Chinese patent medicines are exclusive varieties or exclusive dosage forms.
Even if they are not exclusive varieties, they are affected by factors such as the origin of the medicinal materials, processing technology, formulations and dosage forms.
At present, the evaluation standards for authentic medicinal materials and uniform standards for drug quality evaluation cannot be formed
.
To give a simple example, Moutan Pi has the distinction of "Chuan Dan Pi" and "Feng Dan Pi".
Both are considered authentic medicinal materials.
Which one to choose? How to evaluate good or bad? Many details need to be adjusted according to local conditions
.

In addition, the purchase of Chinese medicines in quantities is also facing some unique problems, such as the particularity of the price mechanism of Chinese patent medicines
.
Because the cultivation of medicinal materials is easily affected by the climate, the price of Chinese medicinal materials fluctuates greatly.
In the case of mass procurement, winning the bid at a low price and a little carelessness may drive the company to lose money and produce it
.
For example, the current price of Panax notoginseng is 195 yuan (based on the commonly used cuts as the standard), and Xuesaitong manufacturers still have about 30% profit margins
.
But if the price of Panax notoginseng rises by 50%, manufacturers must adjust the price, otherwise they may face production losses
.
In this kind of national collective purchasing behavior, how can it be possible for you to adjust prices at will? On the other hand, how to investigate the responsibility for breach of contract due to force majeure breaches such as floods and reductions in production in disaster years will also become a difficult problem that needs to be solved
.

As the saying goes, a coin has two sides
.
If the above-mentioned problem is one side of the coin, how do you look at the other side? Can it be predicted that proprietary Chinese medicines with "clear active ingredients, clear indications, large amounts of use, a high proportion of money, and a good competitive landscape" may be the first batch of proprietary Chinese medicines to be purchased in large quantities? In the future, can we use the "small amount + frequently used" model to start centralized procurement, slowly expand, continue to explore experience, and continuously improve to solve the problems one by one?

Centralized collection of traditional Chinese medicine is on the line

The establishment of the country's first inter-provincial Chinese medicinal materials procurement alliance "Twelve Provinces Chinese Medicinal Materials Purchasing Alliance" is the first step towards "unification of quality standards"
.

Judging from the practice in Shandong Province this time, the Procurement Alliance will build an Internet trading platform for Chinese medicinal materials, with medicinal materials as the source of quality control, and covering Chinese medicinal pieces and Chinese medicinal formula granules, etc.
, through the establishment of Chinese medicinal quality standards, quality identification, full traceability, The seven major systems of quality insurance, Internet trading, Chinese medicine innovation and international exchanges promoted the entire transaction of Chinese medicines, including Chinese medicinal materials, decoction pieces and formula granules, from offline to online
.

This means that Chinese medicinal products that have long been affected by various factors such as variety, place of production, season, processing, etc.
, may usher in a comprehensive upgrade in terms of quality, standards and supervision
.

In the future, after mass procurement is implemented, at least some Chinese medicinal materials companies that "do not focus on quality but only on relationships" will be eliminated, which will force companies to pay attention to the quality of multiple links such as production, processing, storage, and transportation.
Will become a heavyweight intangible brand equity and powerful advertising
.

Faced with the upcoming large-scale procurement of Chinese medicine, the reshuffle of the Chinese medicine industry has been irreversible.
How Chinese medicine manufacturers balance long-term and short-term interests will test the vision and strategy of each enterprise
.

Take the opportunity to eliminate the old model, make great efforts to improve product strength and productivity, strengthen source control and quality assurance, fundamentally strengthen the introduction of new drugs or the promotion of old drugs and new diseases, and then look far to overseas to lead internationalization.
Think about it.
Isn't it fragrant?

About the Author:

Luo Zhibo, Ph.
D.
, graduated from Tsinghua University.
He is currently the chief engineer of the Pharmaceutical Research Institute of Guangzhou Baiyunshan Pharmaceutical Group Co.
, Ltd.
Baiyunshan General Pharmaceutical Factory.
He is mainly engaged in new drug project evaluation and new drug development
.

As the person in charge, he has completed more than 40 new drug project investigations, participated in the introduction of 8 first-class new drug projects, and has successfully introduced 3 projects
.
Presided over the Guangzhou patent work special fund project, as the main research backbone, participated in the national key research and development plan special project, the major consulting project of the Chinese Academy of Engineering, the National Natural Science Foundation project, the Guangdong Province soft science project and other 6 national, provincial and ministerial projects
.
As the first author, he published 8 SCI papers, 2 Chinese scientific papers, 9 conference papers, applied for 13 patents (3 authorized), and participated in the compilation of 2 monographs
.